Skip to main content
SpringerLink
Log in

Antiplatelet Therapy and Anticoagulation

  • Chapter
  • First Online:
Perioperative Hemostasis

  • 2386 Accesses

Abstract

Preoperative withdrawal of antiplatelet (AP) therapy in secondary prevention multiplies the risk of myocardial infarction, stent thrombosis, stroke, or death, by five to ten times. Aspirin is a lifelong therapy and should never be interrupted. Dual AP therapy with aspirin plus clopidogrel, prasugrel, or ticagrelor is essential for at least 6 weeks after coronary revascularization using bare-metal stents, 12 months after treatment for acute coronary syndrome, and 6–12 months after implanting drug-eluting stents. These time spans might even be prolonged in high-risk cases. Elective surgery should be postponed until after these periods. Vital or urgent operations undertaken earlier must be performed under continued dual AP therapy.

Preoperatively, patients might be on prophylactic or therapeutic doses of anticoagulants. The indication for the anticoagulation therapy must be reevaluated in order to balance the thrombotic risk of interrupting against the risk of bleeding when continuing the treatment. A detailed protocol, comprising the pre-, peri-, and postoperative phases needs then to be established. It should include indications regarding anticoagulation reversal, bridging (when necessary), and postoperative reintroduction of the anticoagulant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ageno W, Gallus AS et al (2012) Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e44S–e88S

    PubMed  CAS  PubMed Central  Google Scholar 

  • Albaladejo P, Marret E et al (2011) Non-cardiac surgery in patients with coronary stents: the RECO study. Heart 97(19):1566–1572

    Article  PubMed  Google Scholar 

  • American Society of Anesthesiologists Task Force on Neuraxial Opioids, Horlocker TT et al (2009) Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration. Anesthesiology 110(2):218–230

    PubMed  Google Scholar 

  • Anand SS, Brimble S et al (1997) Management of iliofemoral thrombosis in a pregnant patient with heparin resistance. Arch Intern Med 157(7):815–816

    Article  PubMed  CAS  Google Scholar 

  • Angiolillo DJ, Firstenberg MS et al (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307(3):265–274

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Aradi D, Komocsi A et al (2010) Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 160(3):543–551

    Article  PubMed  CAS  Google Scholar 

  • Artang R, Dieter RS (2007) Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries. Am J Cardiol 99(8):1039–1043

    Article  PubMed  CAS  Google Scholar 

  • Asmis LM, Alberio L et al (2012) Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 129(4):492–498

    Article  PubMed  CAS  Google Scholar 

  • Barash P, Akhtar S (2010) Coronary stents: factors contributing to perioperative major adverse cardiovascular events. Br J Anaesth 105(Suppl 1):i3–i15

    Article  PubMed  Google Scholar 

  • Barrett YC, Wang Z et al (2010) Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104(6):1263–1271

    Article  PubMed  CAS  Google Scholar 

  • Basu D, Gallus A et al (1972) A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287(7):324–327

    Article  PubMed  CAS  Google Scholar 

  • Bates ER, Lau WC et al (2011) Clopidogrel-drug interactions. J Am Coll Cardiol 57(11):1251–1263

    Article  PubMed  CAS  Google Scholar 

  • Berger PB, Bellot V et al (2001) An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac surgery. Am J Cardiol 87(9):1100–1102, A1106, A1109

    Article  PubMed  CAS  Google Scholar 

  • Bhatt DL, Fox KA et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354(16):1706–1717

    Article  PubMed  CAS  Google Scholar 

  • Bijsterveld NR, Moons AH et al (2002) Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106(20):2550–2554

    Article  PubMed  CAS  Google Scholar 

  • Biondi-Zoccai GG, Lotrionte M et al (2006) A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 27(22):2667–2674

    Article  PubMed  Google Scholar 

  • Brey RL (1992) Antiphospholipid antibodies and ischemic stroke. Heart Dis Stroke 1(6):379–382

    PubMed  CAS  Google Scholar 

  • Burger W, Chemnitius JM et al (2005) Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 257(5):399–414

    Article  PubMed  CAS  Google Scholar 

  • Chassot PG, Delabays A et al (2007) Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99(3):316–328

    Article  PubMed  CAS  Google Scholar 

  • Chassot PG, Marcucci C et al (2010) Perioperative antiplatelet therapy. Am Fam Physician 82(12):1484–1489

    PubMed  Google Scholar 

  • Chernoguz A, Telem DA et al (2011) Cessation of clopidogrel before major abdominal procedures. Arch Surg 146(3):334–339

    Article  PubMed  CAS  Google Scholar 

  • Connolly SJ, Ezekowitz MD et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151

    Article  PubMed  CAS  Google Scholar 

  • Dabbagh O, Nagam N et al (2010) Retrievable inferior vena cava filters are not getting retrieved: where is the gap? Thromb Res 126(6):493–497

    Article  PubMed  CAS  Google Scholar 

  • Dangas GD, Caixeta A et al (2011) Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 123(16):1745–1756

    Article  PubMed  Google Scholar 

  • Douketis JD, Berger PB et al (2008) The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):299S–339S

    Article  PubMed  CAS  Google Scholar 

  • Eberli D, Chassot PG et al (2010) Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. J Urol 183(6):2128–2136

    Article  PubMed  Google Scholar 

  • Edson JR, Krivit W et al (1967) Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 70(3):463–470

    PubMed  CAS  Google Scholar 

  • Eerenberg ES, Kamphuisen PW et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579

    Article  PubMed  CAS  Google Scholar 

  • Eisenberg MJ, Richard PR et al (2009) Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 119(12):1634–1642

    Article  PubMed  CAS  Google Scholar 

  • Fujimoto H, Ishimura R et al (2009) Two cases of acute coronary syndrome that occurred by preoperative discontinuation of antiplatelet therapy in the chronic phase after stent implantation. J Cardiol 54(3):470–474

    Article  PubMed  Google Scholar 

  • Gaglia MA Jr, Waksman R (2011) Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. Eur Heart J 32(19):2358–2364

    Article  PubMed  CAS  Google Scholar 

  • Garcia DA, Baglin TP et al (2012) Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e24S–e43S

    PubMed  CAS  PubMed Central  Google Scholar 

  • Gavillet M, Angelillo-Scherrer A (2012) Quantification of the anticoagulatory effect of novel anticoagulants and management of emergencies. Cardiovasc Med 15(5):170–179

    Google Scholar 

  • Gogarten W, Vandermeulen E et al (2010) Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 27(12):999–1015

    Article  PubMed  CAS  Google Scholar 

  • Green D, Hirsh J et al (1994) Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 46(1):89–109

    PubMed  CAS  Google Scholar 

  • Gurbel PA, Bliden KP et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25):2577–2585

    Article  PubMed  CAS  Google Scholar 

  • Hall R, Mazer CD (2011) Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg 112(2):292–318

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, van Aken WG et al (1976) Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 53(4):691–695

    Article  PubMed  CAS  Google Scholar 

  • Jaff MR, McMurtry MS et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123(16):1788–1830

    Article  PubMed  Google Scholar 

  • Jaffer AK, Brotman DJ et al (2010) Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals. Am J Med 123(2):141–150

    Article  PubMed  CAS  Google Scholar 

  • Joner M, Finn AV et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48(1):193–202

    Article  PubMed  Google Scholar 

  • Kearon C, Akl EA et al (2012) Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494S

    PubMed  CAS  PubMed Central  Google Scholar 

  • Korte W, Cattaneo M et al (2011) Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 105(5):743–749

    Article  PubMed  CAS  Google Scholar 

  • Kubitza D, Becka M et al (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78(4):412–421

    Article  PubMed  CAS  Google Scholar 

  • Levine MN, Hirsh J et al (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154(1):49–56

    Article  PubMed  CAS  Google Scholar 

  • Mega JL, Simon T et al (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16):1821–1830

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Mismetti P, Rivron-Guillot K et al (2007) A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism. Chest 131(1):223–229

    Article  PubMed  Google Scholar 

  • Moore M, Power M (2004) Perioperative hemorrhage and combined clopidogrel and aspirin therapy. Anesthesiology 101(3):792–794

    Article  PubMed  Google Scholar 

  • Mourelo R, Kaidar-Person O et al (2008) Hemorrhagic and thromboembolic complications after bariatric surgery in patients receiving chronic anticoagulation therapy. Obes Surg 18(2):167–170

    Article  PubMed  Google Scholar 

  • Nicholson W, Nicholson WJ et al (2010) Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med 170(20):1827–1831

    Article  PubMed  Google Scholar 

  • Nuttall GA, Brown MJ et al (2008) Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 109(4):588–595

    Article  PubMed  Google Scholar 

  • Olson JD, Arkin CF et al (1998) College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 122(9):782–798

    PubMed  CAS  Google Scholar 

  • Patel MR, Mahaffey KW et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891

    Article  PubMed  CAS  Google Scholar 

  • Patrono C, Rocca B (2010) The future of antiplatelet therapy in cardiovascular disease. Annu Rev Med 61:49–61

    Article  PubMed  CAS  Google Scholar 

  • Pengo V, Crippa L et al (2011) Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 106(5):868–876

    Article  PubMed  CAS  Google Scholar 

  • Pharma BS (2009) Xarelto. Summary of product characteristics. www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf. Accessed Mar 2011

  • Price MJ (2009) Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 119(19):2625–2632

    Article  PubMed  Google Scholar 

  • Rabbitts JA, Nuttall GA et al (2008) Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 109(4):596–604

    Article  PubMed  Google Scholar 

  • Samama MM, Contant G et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107(2):379–387

    Article  PubMed  CAS  Google Scholar 

  • Savonitto S, D’Urbano M et al (2010) Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 104(3):285–291

    Article  PubMed  CAS  Google Scholar 

  • Schouten O, van Domburg RT et al (2007) Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 49(1):122–124

    Article  PubMed  Google Scholar 

  • Schulz S, Schuster T et al (2009) Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 30(22):2714–2721

    Article  PubMed  CAS  Google Scholar 

  • Sharma AK, Ajani AE et al (2004) Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 63(2):141–145

    Article  PubMed  Google Scholar 

  • Stangier J, Rathgen K et al (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292–303

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Streiff MB (2000) Vena caval filters: a comprehensive review. Blood 95(12):3669–3677

    PubMed  CAS  Google Scholar 

  • Task Force on Myocardial Revascularization of the European Society of, Cardiology; The European Association for Cardio-Thoracic Surgery; et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31(20):2501–2555

    Article  Google Scholar 

  • Taylor K, Filgate R et al (2011) A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. BJU Int 108(Suppl 2):45–50

    Article  PubMed  Google Scholar 

  • Valgimigli M, Campo G et al (2012) Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125(16):2015–2026

    Article  PubMed  CAS  Google Scholar 

  • van Ryn J, Stangier J et al (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116–1127

    Article  PubMed  Google Scholar 

  • Wallentin L, Becker RC et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057

    Article  PubMed  CAS  Google Scholar 

  • Warkentin TE, Margetts P et al (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119(9):2172–2174

    Article  PubMed  CAS  Google Scholar 

  • Weitz JI (2010) New oral anticoagulants in development. Thromb Haemost 103(1):62–70

    Article  PubMed  CAS  Google Scholar 

  • Whitfield LR, Lele AS et al (1983) Effect of pregnancy on the relationship between concentration and anticoagulant action of heparin. Clin Pharmacol Ther 34(1):23–28

    Article  PubMed  CAS  Google Scholar 

  • Wilson SH, Fasseas P et al (2003) Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 42(2):234–240

    Article  PubMed  Google Scholar 

  • Wiviott SD, Braunwald E et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001–2015

    Article  PubMed  CAS  Google Scholar 

  • Zhang D, He K et al (2009) Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 37(8):1738–1748

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Anesthesiology, Lausanne University Hospital (CHUV), Lausanne, CH-1011, Switzerland

    Pierre-Guy Chassot & Carlo E. Marcucci

  2. Service of Hematology, Lausanne University Hospital (CHUV), Lausanne, CH-1011, Switzerland

    Stefano Barelli, Sabine Blum & Anne Angelillo-Scherrer

Authors
  1. Pierre-Guy Chassot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Barelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sabine Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne Angelillo-Scherrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlo E. Marcucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre-Guy Chassot .

Editor information

Editors and Affiliations

  1. Department of Anesthesiology, University Hospital of Lausanne, Lausanne, Switzerland

    Carlo Enrique Marcucci

  2. Department of Anesthesiology, University Hospital of Lausanne, Lausanne, Switzerland

    Patrick Schoettker

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Chassot, PG., Barelli, S., Blum, S., Angelillo-Scherrer, A., Marcucci, C.E. (2015). Antiplatelet Therapy and Anticoagulation. In: Marcucci, C., Schoettker, P. (eds) Perioperative Hemostasis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55004-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-55004-1_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-55003-4

  • Online ISBN: 978-3-642-55004-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation